Wednesday, October 7th 2015
The 29th North American Cystic Fibrosis Conference starts tomorrow (08/10) in Phoenix. The Consortium will be well represented in what promises to be an exciting conference following a landmrk year for CF research. The Vertex clinical trial data and our own gene therapy clinical trial results will be prominently discussed.
The Consortium has four abstracts being presented at the meeting, two on data from the clinical trial and two on our Wave II Lentiviral research. Professor Eric Alton will present a talk on the clnical trial results in a session on Thursday morning and Prof Uta Griesenbach has a poster on some interesting immunology results from the trial.
Professor Steve Hyde and Uta also have two posters on the production and clinical development of our lentiviral vector.
Professor Alton will also be chairing a rountable discussion on Saturday titled 'Recent Advances in Gene Therapy Relevant to Treatment of CF Lung Disease'. The full Conference schedule can be found here.
The North American Cystic Fibrosis Conference, Phoenix. 10-08 to 10-10.
What is Gene Therapy? (2008): CF gene therapy aims to insert a fully functional CFTR gene into the lung airway cells of people with the condition. Two main types of vector are used to deliver this new copy of the gene. A viral vector, engineered from viral particles or non-viral vectors, plasmid DNA molecules condensed by other chemical entities. More...